They've had a good 7 months to collate and report on results now. Can't be too long away surely.
Anybody recollect why trial targetted 18 to 60 year olds? Was this due to possible other causes of death (in those cases of covid fatality) in over 60s? Appreciate FDA had input into trial design
Starpharmas nasal trial results for viraleze showed benefits in over 49s, but less so under 49. They spun that as adherence to administration in younger population. Be interested to see a comparison with Starpharmas viralze and BIT225.
Rob Thomas, non exec director BIT is chairman at starpharma.
They've had a good 7 months to collate and report on results...
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $48.72M | |||
| Open | High | Low | Value | Volume |
| 5.2¢ | 5.4¢ | 5.2¢ | $2.393K | 44.94K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 19600 | 5.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.6¢ | 188178 | 2 |
View Market Depth
| Last trade - 15.15pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
5.4¢ |
Change
0.000 ( 3.85 %) |
||||
| Open | High | Low | Volume | ||
| 5.4¢ | 5.4¢ | 5.2¢ | 120722 | ||
| Last updated 15.15pm 03/05/2024 ? | |||||
| BIT (ASX) Chart |